Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma
-
- M.S. Czuczman
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- A. Koryzna
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- A. Mohr
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- C. Stewart
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- K. Donohue
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- L. Blumenson
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- Z.P. Bernstein
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- P. McCarthy
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- A. Alam
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- F. Hernandez-Ilizaliturri
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- M. Skipper
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- K. Brown
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- A. Chanan-Khan
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- D. Klippenstein
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- P. Loud
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- M.K. Rock
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- M. Benyunes
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- A. Grillo-Lopez
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
-
- S.H. Bernstein
- From the Roswell Park Cancer Institute, Buffalo, NY; Berlex Laboratories, Richmond; Genentech Inc, San Francisco; and IDEC Pharmaceuticals, San Diego, CA
抄録
<jats:sec><jats:title>Purpose</jats:title><jats:p> To evaluate the safety and efficacy of fludarabine plus rituximab in treatment-naïve or relapsed patients with low-grade and/or follicular non-Hodgkin's lymphoma. </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> This was an open-label, single-arm, single-center phase II study enrolling 40 patients. During the first week of the study, patients received two infusions of rituximab 375 mg/m<jats:sup>2</jats:sup> administered 4 days apart. Seventy-two hours after the second infusion of rituximab, patients received the first of six cycles of fludarabine chemotherapy (25 mg/m<jats:sup>2</jats:sup>/d for 5 days on a 28-day cycle). Single infusions of rituximab were administered 72 hours before the second, fourth, and sixth cycles of fludarabine, and two infusions of rituximab were given 4 weeks after the last cycle of fludarabine. Treatment duration was 26 weeks. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> An overall response rate of 90% (80% complete response rate) was achieved in the intent-to-treat population. Similar response rates were seen in treatment-naïve and previously treated patients. The median duration of response has not been reached at 40+ months. The median follow-up time in this study is 44 months (range, 15 to 66 months). In patients positive for the 14;18 translocation in blood and/or marrow at enrollment, molecular remission was achieved in 88% of cases, with patients remaining negative for up to 4 years to date. Hematologic toxicity was manageable, and except for a 15% incidence of herpes simplex/zoster infections, infectious complications were rare. Nonhematologic toxicities were minimal. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Rituximab plus fludarabine was well tolerated and associated with an excellent complete response rate, including molecular remissions, in patients with low-grade or follicular lymphoma. </jats:p></jats:sec>
収録刊行物
-
- Journal of Clinical Oncology
-
Journal of Clinical Oncology 23 (4), 694-704, 2005-02-01
American Society of Clinical Oncology (ASCO)
- Tweet
キーワード
詳細情報
-
- CRID
- 1363107368949978624
-
- NII論文ID
- 30022791483
-
- ISSN
- 15277755
- 0732183X
-
- データソース種別
-
- Crossref
- CiNii Articles